(Q37700537)

English

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

scientific article published on August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

author name string

Shunmugaperumal Tamilvanan

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Natarajan Livingston Raja

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Biswanath Sa

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sanat Kumar Basu

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Journal of Drug Targeting

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

489-498

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Pure red-cell aplasia and epoetin therapy.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Antibodies against rHuEPO: native and recombinant

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biosimilars: recent developments

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Immunogenicity of protein therapeutics

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Antibody-mediated side effects of recombinant proteins

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biosimilars: policy, clinical, and regulatory considerations.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Pure red cell aplasia due to follow-on epoetin.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Pharmacy and pharmacology of biosimilars.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biosimilars--science, status, and strategic perspective

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Antibodies against erythropoietin and other protein-based therapeutics: an overview

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Inhibitor antibodies to factor VIII and factor IX: management

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Epoetin-associated pure red cell aplasia: past, present, and future considerations

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

The challenge of biosimilars

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Environmental and genetic factors influencing inhibitor development

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Neutralizing antibodies in gene-defective hosts

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Human immune response to recombinant human proteins

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Effects of protein aggregates: an immunologic perspective

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

The first biosimilar epoetin: but how similar is it?

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Biosimilar therapeutics-what do we need to consider?

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Eprex-associated pure red cell aplasia and leachates

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Quantification and significance of protein oxidation in biological samples

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Rationally engineered therapeutic proteins with reduced immunogenicity.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Protein aggregation and its inhibition in biopharmaceutics

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

1 reference

https://api.crossref.org/works/10.3109%2F10611861003649746

21 January 2018

Identifiers

10.3109/10611861003649746

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

release_5hhoayjtgndinjehrjtpz2ykxe

1 reference

https://api.fatcat.wiki/v0/release/5hhoayjtgndinjehrjtpz2ykxe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37700537&oldid=1835374147"